Pentoxifylline reduces tumor necrosis factor-α and HIV-induced vascular endothelial activation

AIDS Research and Human Retroviruses

Volumn 28, Issue 10, 2012, Pages 1207-1215

  Green, Linden Ann ^a   Kim, Chul ^a,c   Gupta, Samir K ^a   Rajashekhar, Gangaraju ^a   Rehman, Jalees ^b   Clauss, Matthias ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PENTOXIFYLLINE; RECOMBINANT GLYCOPROTEIN GP 120; SALSALATE; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY BLOOD VESSEL; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MICROVASCULAR ENDOTHELIAL CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VASCULAR ENDOTHELIUM;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; CHEMOKINE CXCL10; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FEMALE; HIV-1; HUMANS; MALE; PENTOXIFYLLINE; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1; VASODILATOR AGENTS; VIRUS REPLICATION;

EID: 84866664606     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0385     Document Type: Review

References (52)

1. Sackoff JE, Hanna DB, Pfeiffer MR, and Torian LV: Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006;145:397-406.
2. Freiberg MS, Chang CC, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, Rimland D, Goetz MB, Butt AA, Rodriguez Barradas MC, Gibert C, Leaf D, Brown ST, Samet J, Kazis L, Bryant K, and Justice AC: The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes 2011; 4:425-432.
3. Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sorensen HT, and Gerstoft J: Ischemic heart disease in HIV-infected and HIV-uninfected individuals: A population-based cohort study. Clin Infect Dis 2007;44:1625-1631.
4. Triant VA, Lee H, Hadigan C, and Grinspoon SK: Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92:2506-2512.
5. El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, and Neaton JD: Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: A randomized trial. Ann Intern Med 2008;149:289-299.
6. Jong E, Louw S, van Gorp EC, Meijers JC, ten Cate H, and Jacobson BF: The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals. Thromb Haemost 2010;104:1228-1234.
7. Baker JV and Lundgren JD: Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J 2011;32(8):945-951.
8. Skiest DJ, Su Z, Havlir DV, Robertson KR, Coombs RW, Cain P, Peterson T, Krambrink A, Jahed N, McMahon D, and Margolis DM: Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: A prospective study by AIDS Clinical Trials Group 5170. J Infect Dis 2007;195:1426-1436.
9. Bowie AG and O'Neill LA: Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase. J Immunol 2000;165:7180-7188.
10. Koga M, Kai H, Yasukawa H, Kato S, Yamamoto T, Kawai Y, Kusaba K, Seki Y, Kai M, Egashira K, Kataoka Y, and Imaizumi T: Postnatal blocking of interferon-gamma function prevented atherosclerotic plaque formation in apolipo-protein E-knockout mice. Hypertens Res 2007;30:259-267.
11. Clauss M, Sunderkotter C, Sveinbjornsson B, Hippenstiel S, Willuweit A, Marino M, Haas E, Seljelid R, Scheurich P, Suttorp N, Grell M, and Risau W: A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. Blood 2001;97:1321-1329.
12. Rajashekhar G, Grow M, Willuweit A, Patterson CE, and Clauss M: Divergent and convergent effects on gene expression and function in acute versus chronic endothelial activation. Physiol Genomics 2007;1:104-113.
13. Zhang Y, Herbert BS, Rajashekhar G, Ingram DA, Yoder MC, Clauss M, and Rehman J: Premature senescence of highly proliferative endothelial progenitor cells is induced by tumor necrosis factor-alpha via the p38 mitogen-activated protein kinase pathway. FASEB J 2009; 23:1358-1365.
14. Jaruga B, Hong F, Kim WH, and Gao B: IFN-gamma/STAT1 acts as a proinflammatory signal in T cell-mediated hepatitis via induction of multiple chemokines and adhesion molecules: a critical role of IRF-1. Am J Physiol Gastrointest Liver Physiol 2004;287:G1044-1052.
15. Chi D, Henry J, Kelley J, Thorpe R, Smith JK, and Krish-naswamy G: The effects of HIV infection on endothelial function. Endothelium 2000;7:223-242.
16. Toborek M, Lee YW, Pu H, Malecki A, Flora G, Garrido R, Hennig B, Bauer HC, and Nath A: HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J Neurochem 2003;84:169-179.
17. Gupta SK, Johnson RM, Mather KJ, and Dube MP: Anti-Inflammatory Treatment with Pentoxifylline Improves HIV-Related Endothelial Dysfunction: A Pilot Study. 15th Conferences on Retroviruses and Opportunistic Infections, 2008.
18. Gupta SK, Johnson RM, Saha C, Mather KJ, Greenwald ML, Waltz JS, Rehman J, and Dube MP: Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: A pilot study. AIDS 2008;22:653-655.
19. Gupta SK, Johnson RM, Mather KJ, Clauss M, Rehman J, Saha C, Desta Z, and Dube MP: Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: A pilot study. AIDS 2010;24:1377-1380.
20. Kopp E and Ghosh S: Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994;265:956-959.
21. Zhang M, Xu YJ, Saini HK, Turan B, Liu PP, and Dhalla NS: TNF-alpha as a potential mediator of cardiac dysfunction due to intracellular Ca2+-overload. Biochem Biophys Res Commun 2005;327:57-63.
22. Chen YM, Tu CJ, Hung KY, Wu KD, Tsai TJ, and Hsieh BS: Inhibition by pentoxifylline of TNF-alpha-stimulated frac-talkine production in vascular smooth muscle cells: Evidence for mediation by NF-kappa B down-regulation. Br J Pharmacol 2003;138:950-958.
23. Ji Q, Zhang L, Jia H, and Xu J: Pentoxifylline inhibits en-dotoxin-induced NF-kappa B activation and associated production of proinflammatory cytokines. Ann Clin Lab Sci 2004;34:427-436.
24. Tozawa K, Sakurada S, Kohri K, and Okamoto T: Effects of anti-nuclear factor kappa B reagents in blocking adhesion of human cancer cells to vascular endothelial cells. Cancer Res 1995;55:4162-4167.
25. Dansky HM, Barlow CB, Lominska C, Sikes JL, Kao C, Weinsaft J, Cybulsky MI, and Smith JD: Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. Arterioscler Thromb Vasc Biol 2001;21:1662-1667.
26. Schwarz JB, Langwieser N, Langwieser NN, Bek MJ, Seidl S, Eckstein HH, Lu B, Schomig A, Pavenstadt H, and Zohln-hofer D: Novel role of the CXC chemokine receptor 3 in inflammatory response to arterial injury: Involvement of mTORC1. Circ Res 2009;104:189-200.
27. Feldman ED, Weinreich DM, Carroll NM, Burness ML, Feldman AL, Turner E, and Xu H, Alexander HR Jr: Inter-feron gamma-inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells. Ann Surg Oncol 2006;13:125-133.
28. Salvucci O, Basik M, Yao L, Bianchi R, and Tosato G: Evidence for the involvement of SDF-1 and CXCR4 in the disruption of endothelial cell-branching morphogenesis and angiogenesis by TNF-alpha and IFN-gamma. J Leukoc Biol 2004;76:217-226.
29. Dhawan S, Puri RK, Kumar A, Duplan H, Masson JM, and Aggarwal BB: Human immunodeficiency virus-1-tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells. Blood 1997;90:1535-1544.
30. von Sydow M, Sonnerborg A, Gaines H, and Strannegard O: Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses 1991;7:375-378.
31. Arditi M, Kabat W, and Yogev R: Serum tumor necrosis factor alpha, interleukin 1-beta, p24 antigen concentrations and CD4+ cells at various stages of human immunodeficiency virus 1 infection in children. Pediatr Infect Dis J 1991;10:450-455.
32. Basaran Y, Basaran MM, Babacan KF, Ener B, Okay T, Gok H, and Ozdemir M: Serum tumor necrosis factor levels in acute myocardial infarction and unstable angina pectoris. Angiology 1993;44:332-337.
33. Rajan S, Ye J, Bai S, Huang F, and Guo YL: NF-kappaB, but not p38 MAP kinase, is required for TNF-alpha-induced expression of cell adhesion molecules in endothelial cells. J Cell Biochem 2008;105:477-486.
34. Futakuchi M, Ogawa K, Tamano S, Takahashi S, and Shirai T: Suppression of metastasis by nuclear factor kappaB inhibitors in an in vivo lung metastasis model of chemically induced hepatocellular carcinoma. Cancer Sci 2004;95:18-24.
35. Hasebe Y, Thomson LR, and Dorey CK: Pentoxifylline inhibition of vasculogenesis in the neonatal rat retina. Invest Ophthalmol Vis Sci 2000;41:2774-2778.
36. Nikolopoulou A, Tousoulis D, Antoniades C, Petroheilou K, Vasiliadou C, Papageorgiou N, Koniari K, Stefanadi E, Lat-sios G, Siasos G, and Stefanadis C: Common community infections and the risk for coronary artery disease and acute myocardial infarction: Evidence for chronic over-expression of tumor necrosis factor alpha and vascular cells adhesion molecule-1. Int J Cardiol 2008;130:246-250.
37. Gattegno L, Bentata-Peyssare M, Gronowski S, Chaouche K, and Ferriere F: Elevated concentrations of circulating intercellular adhesion molecule 1 (ICAM-1) and of vascular cell adhesion molecule 1 (VCAM-1) in HIV-1 infection. Cell Adhes Commun 1995;3:179-185.
38. Jiang J, Fu W, Wang X, Lin PH, Yao Q, and Chen C: HIV gp120 induces endothelial dysfunction in tumour necrosis factor-alpha-activated porcine and human endothelial cells. Cardiovasc Res 2010;87:366-374.
39. Lucas R, Juillard P, Decoster E, Redard M, Burger D, Donati Y, Giroud C, Monso-Hinard C, De Kesel T, Buurman WA, Moore MW, Dayer JM, Fiers W, Bluethmann H, and Grau GE: Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria. Eur J Immunol 1997;27:1719-1725.
40. Taha H, Grochot-Przeczek A, Was H, Kotlinowski J, Koza-kowskaM, Marek A, Skrzypek K, Lackowska B, Balcerczyk A, Mustafa S, Dulak J, and Jozkowicz A: Modulation of inflammatory response by pentoxifylline is independent of heme oxygenase-1 pathway. J Physiol Pharmacol 2009;60:3-12.
41. Hoie EB, McGuire TR, Leuschen PM, and Zach TL: Pen-toxifylline inhibits tumor necrosis factor-alpha induced synthesis of complement component C3 in human endo-thelial cells. Biol Pharm Bull 2004;27:1670-1673.
42. Fu J, Meng X, He J, and Gu J: Inhibition of inflammation by a p38 MAP kinase targeted cell permeable peptide. Med Chem 2008;4:597-604.
43. Li JC and Lau AS: A role for mitogen-activated protein ki-nase and Ets-1 in the induction of interleukin-10 transcription by human immunodeficiency virus-1 Tat. Immunology 2007;121:337-348.
44. Dohgu S and Banks WA: Lipopolysaccharide-enhanced transcellular transport of HIV-1 across the blood-brain barrier is mediated by the p38 mitogen-activated protein kinase pathway. Exp Neurol 2008;210:740-749.
45. Postadzhiyan AS, Tzontcheva AV, Kehayov I, and Finkov B: Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and their association with clinical outcome, tro-ponin T and C-reactive protein in patients with acute coronary syndromes. Clin Biochem 2008;41:126-133.
46. Silvestro A, Brevetti G, Schiano V, Scopacasa F, and Chiariello M: Adhesion molecules and cardiovascular risk in peripheral arterial disease. Soluble vascular cell adhesion molecule-1 improves risk stratification. Thromb Haemost 2005;93:559-563.
47. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dube MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, and Stein JH: Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008;52:569-76.
48. Diaz PT, Clanton TL, and Pacht ER: Emphysema-like pulmonary disease associated with human immunodeficiency virus infection. Ann Intern Med 1992;116:124-128.
49. Petrache I, Diab K, Knox KS, Twigg HL 3rd, Stephens RS, Flores S, and Tuder RM: HIV associated pulmonary emphysema: A review of the literature and inquiry into its mechanism. Thorax 2008;63:463-469.
50. Mehta NJ, Khan IA, Mehta RN, and Sepkowitz DA: HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest 2000;118:1133-1141.
51. Afessa B Green B: Clinical course, prognostic factors, and outcome prediction for HIV patients in the ICU. The PIP (Pulmonary complications, ICU support, and prognostic factors in hospitalized patients with HIV) study. Chest 2000;118:138-145.
52. Agouridakis P, Kyriakou D, Alexandrakis MG, Prekates A, Perisinakis K, Karkavitsas N, and Bouros D. The predictive role of serum and bronchoalveolar lavage cytokines and adhesion molecules for acute respiratory distress syndrome development and outcome. Respir Res 2002;3:25.